Literature DB >> 9210186

Dynorphin peptides: antagonists of melanocortin receptors.

J M Quillan1, W Sadée.   

Abstract

PURPOSE: To identify possible targets that mediate the non-opioid effects of dynorphin-A (DynA), effects that include inflammation and aggravation of traumatic nerve injury.
METHOD: We examined dynorphin peptides for functional interaction with the closely related melanocortin (MC) system.
RESULTS: DynA-(1-13)NH2 and other related opioid dynorphin peptides antagonize the human MC1, MC3 and MC4 receptors, and an amphibian MC receptor, with dissociation constants (Kd's) of 40 to 150 nM. The affinity of dynorphin's interaction with MC receptors is therefore greater than with other previously proposed non-opioid targets of dynorphin, which require micromolar concentrations. Dynorphin also antagonizes the adrenocorticotropic hormone (ACTH; MC2) receptor and an MC-like receptor endogenous to COS-7 cells, but with lower efficacy. In contrast DynA had no effect on seven control receptors and was only weakly effective at two others. Metabolites of dynorphin derived from cleavage of the amino terminal Tyr residue, such as DynA(2-17), lack opioid activity yet still produce a number of well established non-opioid effects. These des-Tyr derivatives also antagonized each of the five MC receptors examined.
CONCLUSIONS: DynA peptides were found to antagonize MC receptors in vitro with potencies that parallel those reported for pharmacological non-opioid effects of dynorphins in vivo. The combination of DynA and its active metabolites may reach levels sufficient to inhibit MC receptors physiologically. Dynorphin inhibition of MC receptors could prove to be an example of crosstalk between two distinct yet phylogenetically related neurotransmitter systems.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9210186     DOI: 10.1023/a:1012185919153

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  27 in total

1.  Action of light on frog pigment cells in culture.

Authors:  A Daniolos; A B Lerner; M R Lerner
Journal:  Pigment Cell Res       Date:  1990 Jan-Feb

Review 2.  Spinal opioid systems in inflammation.

Authors:  L Stanfa; A Dickenson
Journal:  Inflamm Res       Date:  1995-06       Impact factor: 4.575

Review 3.  Non-opioid effects of dynorphins: possible role of the NMDA receptor.

Authors:  V K Shukla; S Lemaire
Journal:  Trends Pharmacol Sci       Date:  1994-11       Impact factor: 14.819

4.  ACTH-(1-24) and alpha-MSH antagonize feeding behavior stimulated by kappa opiate agonists.

Authors:  R Poggioli; A V Vergoni; A Bertolini
Journal:  Peptides       Date:  1986 Sep-Oct       Impact factor: 3.750

5.  Adrenocorticotropin reversal of experimental hemorrhagic shock is antagonized by morphine.

Authors:  A Bertolini; S Guarini; W Ferrari; E Rompianesi
Journal:  Life Sci       Date:  1986-10-06       Impact factor: 5.037

6.  Nonopiate effects of dynorphin and des-Tyr-dynorphin.

Authors:  J M Walker; H C Moises; D H Coy; G Baldrighi; H Akil
Journal:  Science       Date:  1982-12-10       Impact factor: 47.728

7.  Antagonism of morphine-induced analgesia, tolerance and dependence by alpha-melanocyte-stimulating hormone.

Authors:  P C Contreras; A E Takemori
Journal:  J Pharmacol Exp Ther       Date:  1984-04       Impact factor: 4.030

8.  Induction of analgesia by central administration of ORG 2766, an analog of ACTH4--9.

Authors:  J M Walker; G G Berntson; C A Sandman; A J Kastin; H Akil
Journal:  Eur J Pharmacol       Date:  1981-01-05       Impact factor: 4.432

9.  Dynorphin increases extracellular levels of excitatory amino acids in the brain through a non-opioid mechanism.

Authors:  A I Faden
Journal:  J Neurosci       Date:  1992-02       Impact factor: 6.167

10.  Characterization of non-opioid [3H]dynorphin A-(1-13) binding sites in the rat heart.

Authors:  M Dumont; S Lemaire
Journal:  J Mol Cell Cardiol       Date:  1993-08       Impact factor: 5.000

View more
  6 in total

Review 1.  Genetic variations in human G protein-coupled receptors: implications for drug therapy.

Authors:  W Sadee; E Hoeg; J Lucas; D Wang
Journal:  AAPS PharmSci       Date:  2001

2.  A direct chemical interaction between dynorphin and excitatory amino acids.

Authors:  A Woods; A Zangen
Journal:  Neurochem Res       Date:  2001-04       Impact factor: 3.996

3.  The melanocortin-1 receptor gene mediates female-specific mechanisms of analgesia in mice and humans.

Authors:  Jeffrey S Mogil; Sonya G Wilson; Elissa J Chesler; Andrew L Rankin; Kumar V S Nemmani; William R Lariviere; M Kristina Groce; Margaret R Wallace; Lee Kaplan; Roland Staud; Timothy J Ness; Toni L Glover; Magda Stankova; Alexander Mayorov; Victor J Hruby; Judith E Grisel; Roger B Fillingim
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-27       Impact factor: 11.205

4.  Anesthetic requirement is increased in redheads.

Authors:  Edwin B Liem; Chun-Ming Lin; Mohammad-Irfan Suleman; Anthony G Doufas; Ronald G Gregg; Jacqueline M Veauthier; Gary Loyd; Daniel I Sessler
Journal:  Anesthesiology       Date:  2004-08       Impact factor: 7.892

5.  Perivascular expression and potent vasoconstrictor effect of dynorphin A in cerebral arteries.

Authors:  Éva Ruisanchez; Attila Cselenyák; Rege Sugárka Papp; Tamás Németh; Krisztina Káldi; Péter Sándor; Zoltán Benyó
Journal:  PLoS One       Date:  2012-05-25       Impact factor: 3.240

6.  Plasma membrane poration by opioid neuropeptides: a possible mechanism of pathological signal transduction.

Authors:  O Maximyuk; V Khmyz; C-J Lindskog; V Vukojević; T Ivanova; I Bazov; K F Hauser; G Bakalkin; O Krishtal
Journal:  Cell Death Dis       Date:  2015-03-12       Impact factor: 8.469

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.